IP Library Granted Patent US 8,784,844
Granted Patent B2
US 8,784,844 · App. 12/894,266 · Granted Jul 22, 2014

Arabinogalactan for enhancing the adaptive immune response

Inventors: Bryan Rodriguez (San Antonio, TX); Kevin Q. Owen (Canyon, TX); Ulla Freitas (Lörrach, DE); Jay Udani (Agoura Hills, CA)
Assignee: Lonza Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,784,844
App. No.
12/894,266
Granted
Jul 22, 2014
Kind
B2
Abstract

The present invention discloses a composition containing Arabinogalactan for enhancing the adaptive immune response in subjects to foreign antigen(s) by administering said composition prior, during and after the phase of exposure to said foreign antigen(s). Furthermore, the present invention relates to a vaccination kit comprising a composition comprising Arabinogalactan and a vaccine.

Claims (5)

1. A kit comprising a composition consisting essentially of: 1) the polysaccharide Arabinogalactan and/or at least one Arabinogalactan derivative, and 2) a vaccine, wherein said Arabinogalactan derivative is selected from the group consisting of Arabinogalactan proteins and quaternized forms of Arabinogalactan.

2. The kit according to claim 1 , whereby said vaccine is a pneumococcal vaccine.

3. The kit according to claim 1 , wherein said Arabinogalactan is derived from plants.

4. The kit according to claim 2 , whereby said pneumococcal vaccine is directed against bacteria from the strain Streptococcus pneumoniae.

5. A method for enhancing the adaptive immune response against foreign antigen(s), the method comprising administration of a composition consisting essentially of: 1) the polysaccharide Arabinogalactan and/or at least one Arabinogalactan derivative, and 2) a vaccine, wherein said Arabinogalactan derivative is selected from the group consisting of Arabinogalactan proteins and quaternized forms of Arabinogalactan.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2026
From: LONZA LTD, ALSO KNOWN AS LONZA AG
To: CAPSUGEL SWITZERLAND AG
Reel/Frame 073827/0097 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 23, 2010
From: RODRIGUEZ, BRYAN; OWEN, KEVIN Q.; FREITAS, ULLA; UDANI, JAY
To: LONZA LTD.
Reel/Frame 025395/0844 →
Continuity (2)
Provisional Application 61247204 · Sep 30, 2009
Related Publication 20110076306A1 · Mar 31, 2011